Integrating machine learning, functional assays, and survival analyses, this study provides mechanistic and clinical insight into the EXO1–N4BP2L2 axis and its role in shaping HRD-related therapeutic vulnerabilities. The gene discussed is N4BP2L2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.